阿瑞匹坦预防化疗引起恶心呕吐的疗效及安全性

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (517 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the curative effect and adverse reaction of aprepitant in alleviating nausea and vomiting caused by chemotherapy. Methods 80 patients with cisplatin chemotherapy were randomly divided into study group and control group. The study group used aprepitant combined with the ondansetron hydrochloride, dexamethasone. The control group received palonosetron hydrochlorid combined with ondansetron hydrochloride, and dexamethasone. The curative effect and adverse reactions in the two groups were observed. Results In the study group, complete remission rate and nausea vomiting control rates were 80% and 77.5% respectively, compared with 47.5% and 37.5% in the control group, there was statistically significant difference (P＜0.01). In the two groups, the most adverse reactions mainly included constipation, diarrhea, hiccups, anorexia, fatigue, insomnia, transaminase and elevation, were mild. Conclusions Aprepitant has obvious preventive effect on chemotherapy induced nausea and vomiting, and has clinical application prospects.

Key words： aprepitant chemotherapy vomiting

Received: 23 February 2016

ZTFLH:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SU Dan
	ZHAO Shuixi
	and CAO Jingxu

Cite this article:

SU Dan,ZHAO Shuixi,and CAO Jingxu. Efficacy and safety of aprepitant in patients with nausea and vomiting caused by chemotherapy[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(9): 871-873.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2016/V27/I9/871

[1]	Ettinger D S,Bierman P J,Bradbury B, et al. Antiemesis[J]. J Natl Compr Canc Netw,2007,5(1):12-33.
[2]	Richardson J L, Marks G, Levine A .The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy[J]. J Clin Oncol,1988,6(11):1746-1752.
[3]	Bloechl-Daum B, Deuson R R, Mavros P, et al.Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment[J].J Clin Oncol,2006,24(27):4472-4478.
[4]	Martin A R, Pearson J D, Cai B, et al . Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall[J]. Support Care Cancer,2003,11:522-527.
[5]	中国抗癌协会癌症康复与姑息治疗专业委员会. 肿瘤治疗相关呕吐防治指南[M].北京: 中国协和医科大学出版社,2009: 20-42.
[6]	Saito M,Aogi K,Sekine L,et al.Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial[J]. Lancet Oncol,2009,10(2):115-124.
[7]	Cubeddu L X. Serotonin mechanisms in chemotherapy- induced emesis in cancer patients[J].Oncology,1996, 1:18-25 .
[8]	Wolf H. Preclinical and clinical pharmacology of the 5- HT3 receptor antagonists[J].Scand J Rheumatol Suppl,2000,113:37-45.
[9]	张晓静,张频.肿瘤化疗所致恶心呕吐的发生机制和药物治疗的研究进展[J].癌症进展,2006,4(4):348-354.
[10]	Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference[J]. Ann Oncol, 2010,21(5):232-243.
[11]	Basch E, Prestrud A A, Hesketh P J, et al. Antiemetic American Society Clinical Oncology clinical practice guideline update[J].J Clin Oncol, 2011,29:4189-4198.
[12]	NCCN Clinical Practice Guidelines in Oncology version 1 2014. Antiemesis[M]. National Comprehensive Cancer Network (NCCN),2014.
[13]	Warr D G,Grunberg S M,Gralla R J, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea andvomiting:Pooled data from 2 randomised, double-blind, placebo controlled trials[J].Eur J Cancer,2013,41(9):1278-1285.